IQVIA Holdings (IQV) Earnings Date & Reports

Key Takeaways

• Revenue reached $4,428 million, up 8.0% year-over-year and slightly above the roughly $4.37 billion consensus estimate.
• Adjusted diluted EPS (earnings per share) of $3.34 rose 11.3% year-over-year, topping the consensus estimate of about $3.28.
• Research & Development Solutions net new bookings hit $3.2 billion, up 15% and the strongest clinical quarterly bookings since 2022, with a book-to-bill ratio of 1.2x.
• Management raised full-year 2026 guidance across revenue, Adjusted EBITDA, and Adjusted Diluted EPS.
• Free cash flow of $667 million equaled 120% of Adjusted Net Income, highlighting strong cash conversion.
• You can find more detail on IQVIA's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Explore Trending AI Robots to discover AI-driven trading strategies and market insights.

Earnings Context and Why It Matters

IQVIA Holdings is a leading global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences industry. Its quarterly results are closely watched as a barometer of pharmaceutical research and development (R&D) spending and outsourcing demand. Coming into the report, the company had beaten consensus estimates in each of its trailing four quarters, according to third-party data, supported by improving biotech funding and stronger request-for-proposal (RFP) activity. This third-quarter update therefore matters not only for IQVIA's own trajectory but also as a signal of the broader health of the life sciences outsourcing market, where demand trends, bookings momentum, and margin execution all shape investor expectations.

Reported Results

For the third quarter ended September 30, 2026, IQVIA reported revenue of $4,428 million, an increase of 8.0% on a reported basis and 8.6% at constant currency, compared with $4,100 million a year earlier. The result exceeded the consensus estimate of approximately $4.37 billion.

GAAP (Generally Accepted Accounting Principles) net income was $350 million, with GAAP diluted EPS of $2.10. On an adjusted basis, net income was $557 million and Adjusted Diluted EPS was $3.34, up 11.3% year-over-year and above the consensus estimate of roughly $3.28. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $1,032 million, up 8.7%.

Both operating segments contributed to growth. Commercial Solutions revenue rose 6.9% to $1,789 million, while Research & Development Solutions revenue grew 8.7% to $2,639 million. R&D Solutions net new bookings of $3.2 billion climbed 15% year-over-year, representing a 1.2x book-to-bill ratio. The company also completed a review of inactive trials that reduced contracted backlog by approximately $2.1 billion, leaving R&D Solutions contracted backlog at $32.6 billion. Management expects about $9.4 billion of that backlog to convert to revenue over the next twelve months, up 10% year-over-year.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical resource for those looking to streamline their research process and identify actionable setups across a wide range of securities.

Market Reaction and Investor Sentiment

Despite results that beat consensus estimates on revenue and adjusted EPS, IQVIA shares traded modestly lower following the announcement, reflecting a market that had already priced in considerable optimism heading into the quarter. The stock had climbed to the upper end of its 52-week range in the weeks before the report, and several analysts had raised price targets in the run-up to earnings. Management's commentary was decidedly upbeat, with Chief Executive Officer Ari Bousbib citing favorable demand indicators across biotech funding, RFP flow, clinical trial starts, and U.S. Food and Drug Administration (FDA) approvals. Investor focus quickly shifted to the raised full-year guidance and the strength of forward bookings rather than any single quarter metric.

Forward Outlook and Key Factors to Monitor

IQVIA raised its full-year 2026 guidance, now expecting revenue between $17,350 million and $17,500 million, Adjusted EBITDA between $4,025 million and $4,055 million, and Adjusted Diluted EPS between $12.90 and $13.00. The updated revenue outlook anticipates roughly 250 basis points of contribution from acquisitions expected to close by year-end, along with a modest foreign-exchange tailwind.

Investors should watch several factors going forward. Bookings and the book-to-bill ratio remain the clearest leading indicators of future revenue, and sustained growth above 1.0x would reinforce the demand recovery. The company's AI investments are another area of focus, with management reporting more than 400 AI agents deployed to date as it positions AI as a driver of both revenue growth and operational efficiency.

Margin trends and the pace of pass-through revenue will also matter, since these influence Adjusted EBITDA expansion. Finally, IQVIA plans to host an Investor Day on December 1, 2026, where it is expected to provide a framework for 2027, with detailed guidance anticipated in the February earnings report. These upcoming events should offer further clarity on the durability of the current growth cycle.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations